Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
53.05
+3.75 (7.61%)
May 7, 2026, 4:08 PM HKT
Biocytogen Pharmaceuticals (Beijing) Employees
Biocytogen Pharmaceuticals (Beijing) had 1,443 employees as of December 31, 2025. The number of employees increased by 326 or 29.19% compared to the previous year.
Employees
1,443
Change
326
Growth
29.19%
Revenue / Employee
1.23M HKD
Profits / Employee
228.81K HKD
Market Cap
42.51B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,443 | 326 | 29.19% |
| Jun 30, 2025 | 1,306 | - | - |
| Dec 31, 2024 | 1,117 | 51 | 4.78% |
| Dec 31, 2023 | 1,066 | -282 | -20.92% |
| Dec 31, 2022 | 1,348 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 21,435 |
| Genscript Biotech | 6,165 |
| 3SBio | 6,109 |
| Shanghai Henlius Biotech | 3,762 |
| RemeGen | 3,048 |
| Shanghai Junshi Biosciences | 2,903 |
| Zai Lab | 1,784 |
| Keymed Biosciences | 1,625 |
Biocytogen Pharmaceuticals (Beijing) News
- 3 months ago - Strengthening Translational Research in India: GVSAP and Biocytogen Expand Collaboration - Business Upturn
- 8 months ago - Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions - Financial Post
- 10 months ago - Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website - Business Upturn
- 10 months ago - Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development - Financial Post
- 11 months ago - Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing - Financial Post
- 1 year ago - Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform - Business Upturn
- 1 year ago - Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009) - Financial Post
- 1 year ago - Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors - Financial Post